$4.24 Billion U.S. Insomnia Market by Non-Pharmacological Therapy, Prescription Sleep Aids & OTC Treatment - Forecasts to 2021 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "U.S. Insomnia Market - Forecasts to 2021" report to their offering.

The U.S. insomnia market is categorised into pharmacological treatments and non-pharmacological treatments. The U.S. insomnia pharmacological treatment market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021. The duration of insomnia can be from a day to years. Based on duration, insomnia is divided into three major categories, namely, transient insomnia (less than a month), short term insomnia (between 1 month and 6 months), and chronic insomnia (more than 6 months).

In 2016, the prescription sleep aids segment is expected to account for the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years. However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market. In 2016, the zolpidem segment is expected to account for the largest share of the non-benzodaizepines prescription sleep aids market. However, higher adoption of generic products that are available are cheaper price is negatively affecting the growth of the market.

The over-the-counter sleep aids segment of the U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market include easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid.

Companies Mentioned:

  • Eisai Co., Ltd.
  • Meda Consumer Healthcare, Inc
  • Merck & Co., Inc.
  • Pernix Therapeutics
  • Pfizer Inc.
  • Purdue Pharmaceuticals L.P.
  • Sanofi
  • Takeda Pharmaceuticals Company Ltd.
  • Vanda Pharmaceuticals

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Non-Pharmacological Treatment Market

7 Pharmacological Treatment Market

8 Competitive Landscape

9 Company Profiles

For more information about this report visit http://www.researchandmarkets.com/research/jgq9qr/u_s_insomni

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Over the Counter (OTC) Drugs, Central Nervous System Drugs , Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Over the Counter (OTC) Drugs, Central Nervous System Drugs , Central Nervous System Drugs